Bipartisan congressional lawmakers are celebrating the inclusion of a psychedelics research amendment as part of a must-pass defense bill that’s on the House floor—and a GOP congressman says he has the commitment of the House speaker to fight to broaden the scope of the measure in talks with the Senate.
At a press conference that took place shortly after the House Rules Committee advanced the National Defense Authorization Act (NDAA) with the psychedelics language that were previously attached in the House Armed Services Committee—but blocked floor consideration of an amendment to broaden the provision—Reps. Dan Crenshaw (R-TX), Alexandria Ocasio-Cortez (D-NY) and Lou Correa (D-CA) held a press conference to discuss the development and next steps.
The amendment, which is similar to a standalone bill that Crenshaw filed last month, still needs work, the congressman said. As he explained during a Rules Committee meeting on Tuesday, staff at the prior panel that adopted it as part of NDAA had removed key language on funding and replaced the requirement for Department of Defense (DOD) clinical trials with clinical studies, a meaningful difference.
The Rules Committee declined to accept an amendment to fix the problem, along with more than a dozen other drug
Read full article on Marijuana Moment
